This can be specifically targeted using venetoclax, a Bcl-2 inhibitor which suppresses both TCA cycle and OxPhos, most likely by inhibiting amino acid metabolism which fuels TCA cycle in AML stem cells (28, 43, 44). The gene discussed is BCL2; the disease is acute myeloid leukemia.